Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
Diener, H. C., Dodick, DW, Turkel, Catherine C., Demos, George, DeGryse, Ronald E., Earl, Nancy L., Brin, MF

European Journal of Neurology | March 15, 2014 | Volume: 21 | Issue: 6 | Pages: 851-859

10.1111/ene.12393 | PMID 24628923 Get It

Background and purpose Onabotulinumtoxin A was effective and well tolerated for prophylaxis of headache in patients with chronic migraine ( CM ) in two randomized, double‐blind, placebo‐controlled, phase 3 trials. To further assess the safety and tolerability of onabotulinumtoxin A in CM prophylaxis in adults, the pooled safety data from four double‐blind, placebo‐controlled trials were analyzed. Methods The pooled analysis included two phase 2 and two phase 3 double‐blind, placebo‐controlled trials. The safety population was 2436 patients, 1997 of whom received ≥1 dose of onabotulinumtoxinA. The studies shared similar dosing intervals (approximately 12 weeks) with doses between 75 and 260 U. Safety assessments included adverse events ( AE s), physical examination and clinical laboratory tests. Results Onabotulinumtoxin A was safe and well tolerated, with a low discontinuation rate (3.4%) due to AE s. The majority of patients in this pooled analysis received doses between 150 and 200 U, with an average of 163 U per treatment cycle. Of the 1997 patients who received any onabotulinumtoxin A injections, 1455 patients (72.9%) reported at least one AE . Neck pain (12.6%) was the most common onabotulinumtoxin A ‐associated AE , followed by muscle weakness (8.0%), musculoskeletal stiffness (6.1%) and eyelid ptosis (4.6%). Serious AE s were infrequent, occurring in 5.4% of patients who received any onabotulinumtoxin A treatment and 3.0% of patients receiving placebo. AE s were consistent with the known tolerability profile of onabotulinumtoxin A . Conclusions Multiple treatments with onabotulinumtoxinA at doses of 75–260 U administered every 12 weeks, and up to five treatment cycles, were well tolerated for the prophylaxis of headache in adults with CM .
Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Comı́n-Anduix, Begoña , Chmielowski, Bartosz , Koya, Richard C. , Wu, Zhongqi , Auerbach, Martin, Ng, Charles, Avramis, Earl , Seja, Elizabeth, Villanueva, Arturo, McCannel, Tara A. , Czernin, Johannes, Radu, Caius G. , Wang, Xiaoyan , Gjertson, David W., Cochran, Alistair J., Cornetta, Kenneth , Wong, Deborah Jean Lee, Kaplan‐Lefko, Paula , Hamid, Omid , Cohen, Peter A. , Daniels, Gregory A. , Mukherji, Bijay, Yang, Lili , Zack, Jerome A. , Kohn, Donald B. , Glaspy, John A. , Witte, Owen N. , Baltimore, David , Economou, James S., Ribas, Antoni , Chodon, Thinle, Chodon, Thinle , Ishiyama, Akira , Samlowski, Wolfram E. , Heath, James R. , Chmielowski, Bartosz , Kohn, Donald B

Clinical Cancer Research | March 14, 2014 | Volume: 20 | Issue: 9 | Pages: 2457-2465

10.1158/1078-0432.ccr-13-3017 | PMID 24634374 Get It

Abstract Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. Experimental Design: A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. Results: A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1–specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1–specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. Conclusion: Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses. Clin Cancer Res; 20(9); 2457–65. ©2014 AACR.
Feasibility and Oncologic Control after Percutaneous Image Guided Ablation of Metastatic Renal Cell Carcinoma
Welch, Brian T. , Callstrom, Matthew R. , Schmit, Grant D. , Weisbrod, Adam J. , Lohse, Christine M. , Costello, Brian A. , Olivier, Kenneth R. , Thompson, R. Houston, Boorjian, Stephen A. , Atwell, Thomas D. , Kurup, Anil N, Kohli, Manish , Morris, Jonathan M. , Kurup, A. Nicholas

Journal of Urology | March 14, 2014 | Volume: 192 | Issue: 2 | Pages: 357-363

10.1016/j.juro.2014.03.006 | PMID 24631107 Get It

Development and Characterization of a Differentiated Thyroid Cancer Cell Line Resistant to VEGFR-Targeted Kinase Inhibitors
Isham, Crescent R., Netzel, Brian C., Bossou, Ayoko R., Milosevic, Dragana , Cradic, Kendall W, Grebe, Stefan K., Bible, Keith C.

The Journal of Clinical Endocrinology & Metabolism | March 14, 2014 | Volume: 99 | Issue: 6 | Pages: E936-E943

10.1210/jc.2013-2658 | PMID 24628546 Get It

Long-term natural history of incidentally discovered cavernous malformations in a single-center cohort
Moore, S. Arthur, Brown, Robert D. , Christianson, Teresa J., Flemming, Kelly D. , Flemming, Kelly D

Journal of Neurosurgery | March 14, 2014 | Volume: 120 | Issue: 5 | Pages: 1188-1192

10.3171/2014.1.jns131619 | PMID 24628608 Get It

Object The aim of this study was to determine the prospective hemorrhage rate in a group of retrospectively identified patients in whom symptoms had an unclear relationship to an intracerebral cavernous malformation (ICM) or the malformation itself was an incidental finding. Methods Patients with incidentally discovered ICMs diagnosed between 1989 and 1999 were identified from a previously published cohort. Those with ICMs having an unclear relationship with existing symptoms were also eligible for analysis. Updated clinical and radiographic data pertaining to symptomatic intracerebral hemorrhage related to the ICM or new seizures were obtained through medical chart review and mail survey. In select patients, phone calls were made and death certificates were obtained when possible. The prospective hemorrhage rate was calculated as the number of prospective hemorrhages divided by the number of patient-years of follow-up. Results There were 1311 patient-years of follow-up among the 107 patients (49.5% male; mean age at diagnosis 52 years) eligible for this study. Forty-four patients died in the follow-up period, and the cause of death could be determined in 34 (77%). Two patients had a prospective hemorrhage, which was definitively related to the ICM in only one. Thus, the definitive prospective bleed rate was 0.08% per patient-year. No new seizures developed in any of the patients during the follow-up period. Conclusions The risk of prospective hemorrhage in patients presenting asymptomatically with ICM is very low. This information can be useful in managing such patients and may be most applicable to those with a single ICM.
Lingual Thyroidectomy
Howard, Brittany E. , Moore, Eric J. , Hinni, Michael L.

Annals of Otology, Rhinology & Laryngology | March 14, 2014 | Volume: 123 | Issue: 3 | Pages: 183-187

10.1177/0003489414522976 | PMID 24633944 Get It

Objectives: We report the clinical findings, surgical management, and outcomes for lingual thyroidectomy. Methods: We performed a retrospective case review of lingual thyroidectomy performed at 3 tertiary-care academic referral centers between 1994 and 2012. Results: Nine patients underwent lingual thyroidectomy for symptoms including globus sensation (6 patients), dysphagia (5 patients), and airway obstruction (5 patients). Before surgery, 3 patients had attempted medical suppressive therapy. Lingual thyroidectomy was performed by transoral laser microsurgery in 4 patients, transoral robotic surgery in 3 patients, transoral surgery without microscopic assistance in 1 patient, and an open approach with a modified Sistrunk procedure in 1 patient. Total thyroidectomy was attained in 7 patients, and subtotal resection in 2. The follow-up averaged 8 months, and all patients reported significant improvement in their symptoms. One patient had a recurrence. Complications included postoperative bleeding and epiglottic perforation in 1 patient and airway obstruction secondary to angioedema in another patient. There was no significant difference in operative times between transoral laser microsurgery (91 ± 16 minutes) and transoral robotic surgery (109 ± 35 minutes). Transoral surgery without microscopic assistance and open resection had longer operative times (206 and 246 minutes, respectively). Conclusions: Surgical resection of lingual thyroid glands achieves significant improvement in patient symptoms, with low rates of recurrence. We favor a total lingual thyroidectomy approach with use of either a microscope or a robotic endoscope for optical assistance.
Sexual dimorphism in clinical neurology—predictors of successful lumbar puncture in an “expanding” population
Power, Stephen , Costello, Daniel J. , Tobin, W. Oliver

Obesity | March 14, 2014 | Volume: 22 | Issue: 7 | Pages: 1747-1749

10.1002/oby.20745 | PMID 24634409 Get It

ObjectiveTo determine the proportion of patients who would have an unsuccessful lumbar puncture (LP) due to commonly used LP needles being too short.MethodsThree hundred consecutive adults (age 16–99, mean age 56) who underwent abdominal CT over a 6‐month period were identified. The distance from the skin to the midpoint of the spinal canal was measured in the axial plane, at the level of the iliac crest. This was compared to the length of commonly used spinal needles (88 mm) to assess the number of patients who would have an unsuccessful LP due to this distance being greater than 88 mm from the skin.ResultsIn 72/300 (24%) patients, the midpoint of the spinal canal was greater than 88 mm from the skin. A total of 54/72 (75%) of those patients were female. Of the female participants, 54/159 (34%) had the midpoint of their spinal canal at a distance of greater than 88 mm from the skin. In the male patients, only 18/141 (13%) had a similar finding.ConclusionThis is the first high‐quality study to demonstrate that 24% of the population will have an unsuccessful LP procedure if commonly available spinal needles. We demonstrated that 34% of female patients would have an unsuccessful procedure while, in contrast, a successful LP should be possible in 87% of male patients.
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents
West, Andrew B. , Cowell, Rita M. , Daher, João Paulo Lima , Moehle, Mark S. , Hinkle, Kelly M., Melrose, Heather L. , Standaert, David G. , Volpicelli‐Daley, Laura A.

Journal of Comparative Neurology | March 14, 2014 | Volume: 522 | Issue: 11 | Pages: 2465-2480

10.1002/cne.23583 | PMID 24633735 Get It

ABSTRACTMutations in leucine‐rich repeat kinase 2 (LRRK2) are found in a significant proportion of late‐onset Parkinson's disease (PD) patients. Elucidating the neuroanatomical localization of LRRK2 will further define LRRK2 function and the molecular basis of PD. Here, we utilize recently characterized monoclonal antibodies to evaluate LRRK2 expression in rodent brain regions relevant to PD. In both mice and rats, LRRK2 is highly expressed in the cortex and striatum, particularly in pyramidal neurons of layer V and in medium spiny neurons within striosomes. Overall, rats have a more restricted distribution of LRRK2 compared with mice. Mice, but not rats, show high levels of LRRK2 expression in the substantia nigra pars compacta. Expression of the pathogenic LRRK2‐G2019S protein from mouse bacterial artificial chromosome (BAC) constructs closely mimics endogenous LRRK2 distribution in the mouse brain. However, LRRK2‐G2019S expression derived from human BAC constructs causes LRRK2 to be expressed in additional neuron subtypes in the rat such as striatal cholinergic interneurons and the substantia nigra pars compacta. The distribution of LRRK2 from human BAC constructs more closely resembles descriptions of LRRK2 in humans and nonhuman primates. Computational analyses of DNA regulatory elements in LRRK2 show a primate‐specific promoter sequence that does not exist in lower mammalian species. These noncoding regions may be involved in directing neuronal expression patterns. Together, these studies will aid in understanding the normal function of LRRK2 in the brain and will assist in model selection for future studies. J. Comp. Neurol. 522:2465–2480, 2014. © 2014 Wiley Periodicals, Inc.
Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma
Gustafson, Heather L., Goldman, Bryan, Spier, Catherine, Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Persky, Daniel O. , Miller, Thomas P. , Fisher, Richard I., Briehl, Margaret M., Yao, Song , Lee, Kristy , LeBlanc, Michael , Rimsza, Lisa M. , Habermann, Thomas M. , Slager, Susan L. , Ambrosone, Christine B. , Maurer, Matthew , Cerhan, James R , Link, Brian K

American Journal of Hematology | March 14, 2014 | Volume: 89 | Issue: 6 | Pages: 639-645

10.1002/ajh.23709 | PMID 24633940 Get It

Variable survival outcomes are seen following treatment for aggressive non‐Hodgkin lymphoma (NHL). This study examined whether outcomes for aggressive B‐cell NHL are associated with single nucleotide polymorphisms (SNPs) in oxidative stress‐related genes, which can alter drug metabolism and immune responses. Genotypes for 53 SNPs in 29 genes were determined for 337 patients given anthracycline‐based therapies. Their associations with progression‐free survival (PFS) and overall survival (OS) were estimated by Cox proportional hazard regression; associations with hematologic toxicity were estimated by logistic regression. To validate the findings, the top three SNPs were tested in an independent cohort of 572 DLBCL patients. The top SNPs associated with PFS in the discovery cohort were the rare homozygotes for MPO rs2243828 (hazard ratio [HR] = 1.87, 95% confidence interval [CI] = 1.14–3.06, P = 0.013), AKR1C3 rs10508293 (HR = 2.09, 95% CI = 1.28–3.41, P = 0.0032) and NCF4 rs1883112 (HR = 0.66, 95% CI = 0.43–1.02, P = 0.06). The association of the NCF4 SNP with PFS was replicated in the validation dataset (HR = 0.66, 95% CI = 0.44–1.01, P = 0.05) and the meta‐analysis was significant (HR = 0.66, 95% CI = 0.49–0.89, P < 0.01). The association of the MPO SNP was attenuated in the validation dataset, while the meta‐analysis remained significant (HR = 1.64, 95% CI = 1.12–2.41). These two SNPs showed similar trends with OS in the meta‐analysis (for NCF4, HR = 0.72, 95% CI = 0.51–1.02, P = 0.07 and for MPO, HR = 2.06, 95% CI = 1.36–3.12, P < 0.01). In addition, patients with the rare homozygote of the NCF4 SNP had an increased risk of hematologic toxicity. We concluded that genetic variations in NCF4 may contribute to treatment outcomes for patients with aggressive NHL. Am. J. Hematol. 89:639–645, 2014. © 2014 Wiley Periodicals, Inc.
Childhood and Adolescent B-Cell Lymphoma: Bench to Bedside and Back to Bench
Miles, Rodney R., Galardy, Paul J. , Giulino‐Roth, Lisa , Goldman, Stanton, Cairo, Mitchell S.

Lost in Translation | March 14, 2014 | Volume: No volume available | Issue: No issue available | Pages: 247-285

10.1142/9789814489072_0011 Get It